Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous daratumumab versus active monitoring in high-risk smoldering multiple myeloma
NL-OMON55580Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab in smoldering multiple myeloma (SMM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started May 2018; status: recruiting.
02
Drugs
daratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NL-OMON55580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55580.